公开(公告)号：US10131653B2

公开(公告)日：2018-11-20

申请号：US15568644

申请日：2016-04-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taku Kamei ,  Yasuyoshi Arikawa ,  Tomohiro Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Takashi Miki ,  Jinichi Yonemori ,  Yuya Oguro ,  Takahiro Sugimoto ,  Masaki Seto ,  Goushi Nishida ,  Makoto Kamata ,  Hiroshi Imoto

IPC: C07D413/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14 ,  A61P25/20 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61K31/553

Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US12122815B2

公开(公告)日：2024-10-22

申请号：US17279266

申请日：2019-09-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hiroshi Imoto ,  Mari Adachi ,  Yoko Kanematsu ,  Taiji Asami ,  Ayumu Niida ,  Naoki Nishizawa ,  Derek Cecil Cole ,  Mack Flinspach ,  Nick Scorah ,  Abhijit Suresh Bhat

IPC: C07K14/575 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K38/00 ,  A61K47/02 ,  A61P1/08

CPC classification number: C07K14/575 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2059 ,  A61K47/02 ,  A61P1/08 ,  A61K38/00

Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 328-893.